Short Interest in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Declines By 42.4%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 2,700,000 shares, a drop of 42.4% from the June 30th total of 4,690,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 2.2 days.

Institutional Trading of Marinus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Values First Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 52,257 shares during the last quarter. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the second quarter worth $34,000. Jacobs Levy Equity Management Inc. acquired a new position in Marinus Pharmaceuticals during the first quarter worth $384,000. Avoro Capital Advisors LLC raised its holdings in Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after purchasing an additional 990,607 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares during the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MRNS shares. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Truist Financial restated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $13.79.

Marinus Pharmaceuticals Price Performance

Shares of Marinus Pharmaceuticals stock traded up $0.01 during trading on Friday, reaching $1.43. The company’s stock had a trading volume of 174,678 shares, compared to its average volume of 1,314,470. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $11.26. The company has a market capitalization of $78.55 million, a P/E ratio of -0.54 and a beta of 1.12. The business has a 50 day moving average price of $1.38 and a 200-day moving average price of $5.25.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.68). Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. The firm had revenue of $7.68 million for the quarter, compared to the consensus estimate of $8.61 million. As a group, sell-side analysts anticipate that Marinus Pharmaceuticals will post -1.87 EPS for the current year.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.